What is the Sudeep Pharma PE ratio today?
Sudeep Pharma's PE ratio is 63.8 at the 30 October 2026 close (₹1,068.30 a share): a market capitalisation of ₹12,059 crore divided by consolidated net profit of ₹189 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹173 crore) it is 69.7.
What is the Sudeep Pharma debt to equity ratio?
Sudeep Pharma's debt-to-equity ratio was 0.19 on 30 September 2026: borrowings of ₹188 crore against total equity of ₹973 crore. A year earlier, on 30 September 2025, it was 0.19.
What is the Sudeep Pharma net worth?
Sudeep Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹957 crore on 30 September 2026, up 32.2% from ₹724 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹12,059 crore at the 30 October 2026 close.
What is the Sudeep Pharma PB ratio (price to book value)?
Sudeep Pharma's price-to-book (PB) ratio is 12.60 at the 30 October 2026 close: a market capitalisation of ₹12,059 crore divided by shareholders' equity (book value) of ₹957 crore on 30 September 2026. That is a book value of ₹84.81 per share against a share price of ₹1,068.30.
What is the Sudeep Pharma book value per share?
Sudeep Pharma's book value per share was ₹84.81 on 30 September 2026: shareholders' equity of ₹957 crore divided by the 11.29 crore shares in issue. The share price at the 30 October 2026 close was ₹1,068.30.
What is the Sudeep Pharma shareholding pattern?
On 30 September 2026, Sudeep Pharma's shares were held by promoters 76.15%, foreign portfolio investors (FII/FPI) 2.93%, domestic institutions (DII) 14.05% (including mutual funds at 7.43%) and retail and other non-institutional investors 6.87%.
What is the Sudeep Pharma market cap?
Sudeep Pharma's market capitalisation was ₹12,059 crore at the 30 October 2026 close: 11.29 crore shares at ₹1,068.30 each.
What is the Sudeep Pharma dividend in 2026 and its record date?
In 2026, Sudeep Pharma has declared one dividend: ₹1.50 with record date 23 July 2026.
What is the Sudeep Pharma promoter holding?
Promoters held 76.15% of Sudeep Pharma on 30 September 2026, unchanged from the previous quarter, according to the shareholding pattern filed with NSE.
Is Sudeep Pharma debt free?
No. Sudeep Pharma had borrowings of ₹188 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.19. Its cash and current investments were ₹115 crore, so its net debt was ₹72.5 crore.
What is the Sudeep Pharma free cash flow?
In FY26, Sudeep Pharma generated ₹69.6 crore of cash from operations and spent ₹118 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹48.6 crore.
What is the Sudeep Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Sudeep Pharma's consolidated net profit was ₹173 crore, on revenue from operations of ₹642 crore.
What is the Sudeep Pharma EPS?
Sudeep Pharma's basic earnings per share (EPS) were ₹15.50 in FY26.
What are the Sudeep Pharma latest quarterly results?
Sudeep Pharma's latest results are for Q2 FY27 (July–September 2026): consolidated net profit ₹51.8 crore, up 13.3% from ₹45.7 crore in Q2 FY26; revenue from operations ₹197 crore, up 20.9% year on year.
When are the Sudeep Pharma next results?
Sudeep Pharma has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Sudeep Pharma compare with its peers?
On FY26 consolidated figures, against Sudarshan Chemical Industries, Styrenix Performance Materials and Sharda Cropchem: Sudeep Pharma's operating margin of 32.2% is the highest of the four (Sudarshan Chemical Industries 2.5%, Styrenix Performance Materials 6.7%, Sharda Cropchem 14.3%; peer average 7.8%).
How does the Sudeep Pharma PE ratio compare with its peers?
At the 30 October 2026 closing prices, on FY26 net profit, Sudeep Pharma's PE ratio is 69.7, the second highest of the four: Sudarshan Chemical Industries 355.1, Styrenix Performance Materials 16.9 and Sharda Cropchem 8.8, a peer average of 126.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Sudeep Pharma vs Sudarshan Chemical Industries: how do they compare?
In FY26, Sudeep Pharma earned net profit of ₹173 crore on revenue of ₹642 crore, against ₹22.3 crore on ₹9,787 crore for Sudarshan Chemical Industries. Sudeep Pharma's operating margin was 32.2% (Sudarshan Chemical Industries 2.5%). At the 30 October 2026 close, Sudeep Pharma's market capitalisation was ₹12,059 crore against ₹7,918 crore for Sudarshan Chemical Industries, and its PE ratio on FY26 profit 69.7 against 355.1.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
